Literature DB >> 9709281

Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit.

K Kerlikowske1.   

Abstract

In randomized controlled trials, screening mammography has been shown to reduce mortality from breast cancer about 25% to 30% among women aged 50 to 69 years after only five to six years from the initiation of screening. Among women aged 40 to 49 years, trials have reported no reduction in breast cancer mortality after seven to nine years from the initiation of screening; after 10 to 14 years there is a 16% reduction in breast cancer mortality. Given that the incidence of breast cancer for women aged 40 to 49 years is lower and the potential benefit from mammography screening smaller and delayed, the absolute number of deaths prevented by screening women aged 40 to 49 years is much less than in screening women aged 50 to 69 years. Because the absolute benefit of screening women aged 40 to 49 years is small and there is concern that the harms are substantial, the focus should be to help these women make informed decisions about screening mammography by educating them of their true risk of breast cancer and the potential benefits and risks of screening.

Entities:  

Mesh:

Year:  1997        PMID: 9709281     DOI: 10.1093/jncimono/1997.22.79

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  20 in total

Review 1.  Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

Authors:  J Ringash
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

2.  Waiting for a diagnosis after an abnormal screening mammogram. SMPBC diagnostic process workgroup. Screening Mammography Program of British Columbia.

Authors:  I A Olivotto; L Kan; S King
Journal:  Can J Public Health       Date:  2000 Mar-Apr

3.  Changing Beliefs and Practices in Women With Breast Cancer in China.

Authors:  Michele A Gadd
Journal:  Oncologist       Date:  2015-08-07

Review 4.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  PAM50 and Risk of Recurrence Scores for Interval Breast Cancers.

Authors:  Samantha Puvanesarajah; Sarah J Nyante; Cherie M Kuzmiak; Mengjie Chen; Chiu-Kit Tse; Xuezheng Sun; Emma H Allott; Erin L Kirk; Lisa A Carey; Charles M Perou; Andrew F Olshan; Louise M Henderson; Melissa A Troester
Journal:  Cancer Prev Res (Phila)       Date:  2018-04-05

6.  Number of mammography cases read per year is a strong predictor of sensitivity.

Authors:  Wasfi I Suleiman; Sarah J Lewis; Dianne Georgian-Smith; Michael G Evanoff; Mark F McEntee
Journal:  J Med Imaging (Bellingham)       Date:  2014-05-07

Review 7.  Breast cancer screening in the era of density notification legislation: summary of 2014 Massachusetts experience and suggestion of an evidence-based management algorithm by multi-disciplinary expert panel.

Authors:  Phoebe E Freer; Priscilla J Slanetz; Jennifer S Haas; Nadine M Tung; Kevin S Hughes; Katrina Armstrong; A Alan Semine; Susan L Troyan; Robyn L Birdwell
Journal:  Breast Cancer Res Treat       Date:  2015-08-20       Impact factor: 4.872

8.  Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and digital breast tomosynthesis.

Authors:  Benedikt Schaefgen; Joerg Heil; Richard G Barr; Marcus Radicke; Aba Harcos; Christina Gomez; Anne Stieber; André Hennigs; Alexandra von Au; Julia Spratte; Geraldine Rauch; Joachim Rom; Florian Schütz; Christof Sohn; Michael Golatta
Journal:  Eur Radiol       Date:  2018-01-04       Impact factor: 5.315

9.  A randomized trial of three videos that differ in the framing of information about mammography in women 40 to 49 years old.

Authors:  Carmen L Lewis; Michael P Pignone; Stacey L Sheridan; Stephen M Downs; Linda S Kinsinger
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

10.  Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk?

Authors:  Jennifer S Haas; Celia P Kaplan; Steven E Gregorich; Eliseo J Pérez-Stable; Genevieve Des Jarlais
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.